Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combat...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:c17d6b59e6564653a2e5d1bde94e5ef0 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:c17d6b59e6564653a2e5d1bde94e5ef02021-12-02T19:37:59ZLiterature Overview of the IL-17 Inhibition from Psoriasis to COVID-191178-7031https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef02021-11-01T00:00:00Zhttps://www.dovepress.com/literature-overview-of-the-il-17-inhibition-from-psoriasis-to-covid-19-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combatting the cytokine storm triggered by SARS-CoV-2. From dermato-epidemiological studies conducted on psoriatic and other rheumatological patients, IL-17 inhibitors seem to attenuate or even prevent the cytokine storm and thus ICU referral. Furthermore, both in-vivo and in-vitro experiments suggest that IL-17 plays a key role in SARS-CoV-2 infection progression. Due to this evidence, we decided to summarize the literature findings on IL-17 inhibitors and COVID-19, maintaining psoriasis as the referral disease to better understand the extent of drug effects on the immune system.Keywords: biologics, COVID-19, psoriasis, therapy, IL-17Zou YMeng ZDove Medical Pressarticlebiologicscovid-19psoriasistherapyil-17PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 5611-5618 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
biologics covid-19 psoriasis therapy il-17 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
spellingShingle |
biologics covid-19 psoriasis therapy il-17 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Zou Y Meng Z Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19 |
description |
Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combatting the cytokine storm triggered by SARS-CoV-2. From dermato-epidemiological studies conducted on psoriatic and other rheumatological patients, IL-17 inhibitors seem to attenuate or even prevent the cytokine storm and thus ICU referral. Furthermore, both in-vivo and in-vitro experiments suggest that IL-17 plays a key role in SARS-CoV-2 infection progression. Due to this evidence, we decided to summarize the literature findings on IL-17 inhibitors and COVID-19, maintaining psoriasis as the referral disease to better understand the extent of drug effects on the immune system.Keywords: biologics, COVID-19, psoriasis, therapy, IL-17 |
format |
article |
author |
Zou Y Meng Z |
author_facet |
Zou Y Meng Z |
author_sort |
Zou Y |
title |
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19 |
title_short |
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19 |
title_full |
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19 |
title_fullStr |
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19 |
title_full_unstemmed |
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19 |
title_sort |
literature overview of the il-17 inhibition from psoriasis to covid-19 |
publisher |
Dove Medical Press |
publishDate |
2021 |
url |
https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef0 |
work_keys_str_mv |
AT zouy literatureoverviewoftheil17inhibitionfrompsoriasistocovid19 AT mengz literatureoverviewoftheil17inhibitionfrompsoriasistocovid19 |
_version_ |
1718376349598482432 |